β-Amyrin

β-Amyrin shows effectively counteract amyloid β (Aβ)-induced impairment of long-term potentiation (LTP). β-Amyrin is a promising candidate for Alzheimer's disease (AD) research. β-Amyrin exhibits anti-inflammatory effects, protective activity against pulmonary fibrosis, and notable antibacterial capabilities. β-Amyrin is an orally active natural triterpenoid compound^[1][2][3][4]. In Vitro:β-Amyrin (1-100 μM, 0-80 min) blocks Aβ-induced synaptic dysfunction in the hippocampal tissues of mice^[1].
β-Amyrin (1-10 μg, 24 h 15 min) shows antioxidant activity in cultured hPBMCs (human peripheral blood mononuclear cells)^[2].
β-Amyrin (5-20 μg/mL, 16-24 h) significantly inhibits PGE2 (HY-101952), IL-6 secretion and NF-κB activation dose-dependently in LPS-induced hPBMCs^[2].
β-Amyrin (5 μM, 2 h) exhibits antibacterial mode of action, leading promoting apoptosis-like death in E. coli by producing ROS. In Vivo:β-Amyrin (4 mg/kg, p.o., daily, 5 days) ameliorates object recognition memory deficit and neurogenesis impairments in the hippocampus of Aβ-induced AD model mice^[1].
β-Amyrin (20-100 μg, i.p.) inhibits carrageenan-induced paw edema of rats^[2].
β-Amyrin (20-80 mg/kg, i.g., daily, 5 days) has a potent efficacy in protecting against BLM-induced mice pulmonary fibrosis via suppressing inflammatory response and oxidative stress^[3].
Pharmacokinetic parameters of β-Amyrin in rats

	β-Amyrin standard IV (group 3)	β-Amyrin standard oral dose (group 2)
Dose (mg kg−1)	1	3	300 (equivalent of 3mg kg−1 β-amyrin)
V (ml kg−1)	1317
AUC0→24 h (min μg ml−1)	411	10.6	47.3
Cl (ml min−1 kg−1)	2.04
t1/2λZ (h)	10.2	10.3	8.3
MRT0→24 h (h) (h)	8	8.5	8.7
Cmax (ng ml−1) (h) (h)		18.7	75
tmax (h)	-	3 (n = 2) or 5 (n = 1)	3 (n = 3) or 5 (n = 1)
F (%)		0.86	3.83